Efficacy and safety of neoadjuvant chemotherapy combined with PD-1 antibody for esophageal squamous cell carcinoma in the real world.
10.3760/cma.j.cn112152-20210806-00586
- Author:
Pu Yuan WU
1
;
Tao WANG
2
;
Bao Jun CHEN
2
;
Min Ke SHI
2
;
Bin HUANG
1
;
Nan Die WU
1
;
Liang QI
1
;
Xiao Feng CHANG
1
;
Li Feng WANG
1
;
Bao Rui LIU
1
;
Wei REN
1
Author Information
1. The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
2. Departement of General Thoracic Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China.
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
Immunotherapy;
Neoadjuvant therapy;
Real world study;
Safety;
Therapeutic effect
- MeSH:
Humans;
Antibodies/therapeutic use*;
Antineoplastic Combined Chemotherapy Protocols;
Carcinoma, Squamous Cell/surgery*;
Cisplatin;
Esophageal Neoplasms/surgery*;
Esophageal Squamous Cell Carcinoma/drug therapy*;
Immune Checkpoint Inhibitors/therapeutic use*;
Neoadjuvant Therapy;
Programmed Cell Death 1 Receptor/therapeutic use*;
Retrospective Studies;
Treatment Outcome
- From:
Chinese Journal of Oncology
2023;45(2):170-174
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with programmed death-1 (PD-1) antibody in operable, borderline or potentially resectable locally advanced esophageal squamous cell carcinoma(ESCC) in the real world. Methods: The study retrospectively analyzed 28 patients with operable or potentially resectable locally advanced ESCC patients treated with preoperative chemotherapy combined with PD-1 inhibitor in Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School from April 2020 to March 2021. According to the clinical TNM staging system of the 8th edition of the American Joint Committee on Cancer, there were 1, 15, 10, 1 and 1 case of stage Ⅱ, Ⅲ, ⅣA, ⅣB and unknown stage respectively. The treatment was two cycle of dual drug chemotherapy regimen including taxane plus platinum or fluorouracil combined with PD-1 antibody followed by tumor response assessment and surgery if the patient was eligible for resection. Results: Of the 28 patients, 1, 2, 3 and 4 cycles of chemotherapy combined with PD-1 antibody treatment completed in 1, 21, 5, and 1 patient, respectively. Objective response rate (ORR) was 71.4% (20/28), and disease control rate (DCR) was 100% (28/28). The incidence of adverse events exceeding grade 3 levels was 21.4% (6/28), including 3 neutropenia, 1 leukopenia, 1 thrombocytopenia and 1 immune hepatitis. There was no treatment-related death. Of the 23 patients underwent surgery, R0 resection rate was 87.0% (20/23), 13 patients had down staged to the T1-2N0M0 I stage, the pCR rate was 17.3% (4/23), and the pCR rate of primary tumor was 21.7% (5/23). Four patients received definitive chemoradiotherapy. One patient rejected surgery and other treatment after achieved PR response. Conclusion: Neoadjuvant chemotherapy combined PD-1 inhibitor is safe and has high efficacy in operable, borderline or potentially resectable locally advanced ESCC, and it is a promising regimen.
